vs
Side-by-side financial comparison of Life Time Group Holdings, Inc. (LTH) and Medpace Holdings, Inc. (MEDP). Click either name above to swap in a different company.
Life Time Group Holdings, Inc. is the larger business by last-quarter revenue ($745.1M vs $708.5M, roughly 1.1× Medpace Holdings, Inc.). Medpace Holdings, Inc. runs the higher net margin — 19.1% vs 16.5%, a 2.6% gap on every dollar of revenue. On growth, Medpace Holdings, Inc. posted the faster year-over-year revenue change (32.0% vs 12.3%). Medpace Holdings, Inc. produced more free cash flow last quarter ($188.1M vs $-64.6M). Over the past eight quarters, Medpace Holdings, Inc.'s revenue compounded faster (17.7% CAGR vs 11.7%).
Life Time Group Holdings, Inc. operates a network of premium athletic, fitness and wellness destinations across the United States. It offers diverse services including state-of-the-art gym facilities, group exercise classes, personal training, spa treatments, nutrition coaching, youth programs and co-working spaces for consumers pursuing holistic healthy lifestyles.
Medpace Holdings, Inc. is a global clinical research organization (CRO) based in Cincinnati, Ohio, employing approximately 6,000 people. Operating under a full-service model, the company also offers global central laboratory, imaging core laboratory, and bioanalytical laboratory services, as well as a Phase I unit located on its headquarters and clinical research campus in Cincinnati, Ohio.
LTH vs MEDP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $745.1M | $708.5M |
| Net Profit | $123.0M | $135.1M |
| Gross Margin | 49.1% | — |
| Operating Margin | 17.4% | 21.6% |
| Net Margin | 16.5% | 19.1% |
| Revenue YoY | 12.3% | 32.0% |
| Net Profit YoY | 231.0% | 15.5% |
| EPS (diluted) | $0.55 | $4.65 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $745.1M | $708.5M | ||
| Q3 25 | $782.6M | $659.9M | ||
| Q2 25 | $761.5M | $603.3M | ||
| Q1 25 | $706.0M | $558.6M | ||
| Q4 24 | $663.3M | $536.6M | ||
| Q3 24 | $693.2M | $533.3M | ||
| Q2 24 | $667.8M | $528.1M | ||
| Q1 24 | $596.7M | $511.0M |
| Q4 25 | $123.0M | $135.1M | ||
| Q3 25 | $102.4M | $111.1M | ||
| Q2 25 | $72.1M | $90.3M | ||
| Q1 25 | $76.1M | $114.6M | ||
| Q4 24 | $37.2M | $117.0M | ||
| Q3 24 | $41.4M | $96.4M | ||
| Q2 24 | $52.8M | $88.4M | ||
| Q1 24 | $24.9M | $102.6M |
| Q4 25 | 49.1% | — | ||
| Q3 25 | 47.1% | — | ||
| Q2 25 | 47.0% | — | ||
| Q1 25 | 47.5% | — | ||
| Q4 24 | 48.2% | — | ||
| Q3 24 | 46.5% | — | ||
| Q2 24 | 46.8% | — | ||
| Q1 24 | 46.1% | — |
| Q4 25 | 17.4% | 21.6% | ||
| Q3 25 | 17.3% | 21.5% | ||
| Q2 25 | 14.2% | 20.9% | ||
| Q1 25 | 15.2% | 20.3% | ||
| Q4 24 | 13.1% | 23.4% | ||
| Q3 24 | 13.5% | 21.1% | ||
| Q2 24 | 15.7% | 19.9% | ||
| Q1 24 | 12.1% | 20.4% |
| Q4 25 | 16.5% | 19.1% | ||
| Q3 25 | 13.1% | 16.8% | ||
| Q2 25 | 9.5% | 15.0% | ||
| Q1 25 | 10.8% | 20.5% | ||
| Q4 24 | 5.6% | 21.8% | ||
| Q3 24 | 6.0% | 18.1% | ||
| Q2 24 | 7.9% | 16.7% | ||
| Q1 24 | 4.2% | 20.1% |
| Q4 25 | $0.55 | $4.65 | ||
| Q3 25 | $0.45 | $3.86 | ||
| Q2 25 | $0.32 | $3.10 | ||
| Q1 25 | $0.34 | $3.67 | ||
| Q4 24 | $0.17 | $3.67 | ||
| Q3 24 | $0.19 | $3.01 | ||
| Q2 24 | $0.26 | $2.75 | ||
| Q1 24 | $0.12 | $3.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $204.8M | $497.0M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $3.1B | $459.1M |
| Total Assets | $8.0B | $2.0B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $204.8M | $497.0M | ||
| Q3 25 | $218.9M | $285.4M | ||
| Q2 25 | $175.5M | $46.3M | ||
| Q1 25 | $59.0M | $441.4M | ||
| Q4 24 | $10.9M | $669.4M | ||
| Q3 24 | $120.9M | $656.9M | ||
| Q2 24 | $34.5M | $510.9M | ||
| Q1 24 | $18.6M | $407.0M |
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.5B | — | ||
| Q4 24 | $1.5B | — | ||
| Q3 24 | $1.7B | — | ||
| Q2 24 | $1.8B | — | ||
| Q1 24 | $2.0B | — |
| Q4 25 | $3.1B | $459.1M | ||
| Q3 25 | $3.0B | $293.6M | ||
| Q2 25 | $2.9B | $172.4M | ||
| Q1 25 | $2.7B | $593.6M | ||
| Q4 24 | $2.6B | $825.5M | ||
| Q3 24 | $2.6B | $881.4M | ||
| Q2 24 | $2.4B | $763.6M | ||
| Q1 24 | $2.3B | $671.5M |
| Q4 25 | $8.0B | $2.0B | ||
| Q3 25 | $7.8B | $1.8B | ||
| Q2 25 | $7.6B | $1.6B | ||
| Q1 25 | $7.3B | $1.9B | ||
| Q4 24 | $7.2B | $2.1B | ||
| Q3 24 | $7.2B | $2.1B | ||
| Q2 24 | $7.1B | $1.9B | ||
| Q1 24 | $7.1B | $1.8B |
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.51× | — | ||
| Q2 25 | 0.53× | — | ||
| Q1 25 | 0.56× | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | 0.64× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.87× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $239.9M | $192.7M |
| Free Cash FlowOCF − Capex | $-64.6M | $188.1M |
| FCF MarginFCF / Revenue | -8.7% | 26.6% |
| Capex IntensityCapex / Revenue | 40.9% | 0.6% |
| Cash ConversionOCF / Net Profit | 1.95× | 1.43× |
| TTM Free Cash FlowTrailing 4 quarters | $-21.0M | $681.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $239.9M | $192.7M | ||
| Q3 25 | $251.1M | $246.2M | ||
| Q2 25 | $195.7M | $148.5M | ||
| Q1 25 | $183.9M | $125.8M | ||
| Q4 24 | $163.1M | $190.7M | ||
| Q3 24 | $151.1M | $149.1M | ||
| Q2 24 | $170.4M | $116.4M | ||
| Q1 24 | $90.4M | $152.7M |
| Q4 25 | $-64.6M | $188.1M | ||
| Q3 25 | $28.6M | $235.5M | ||
| Q2 25 | $-26.3M | $142.4M | ||
| Q1 25 | $41.4M | $115.8M | ||
| Q4 24 | $26.8M | $183.0M | ||
| Q3 24 | $64.0M | $138.5M | ||
| Q2 24 | $26.1M | $103.5M | ||
| Q1 24 | $-66.4M | $147.2M |
| Q4 25 | -8.7% | 26.6% | ||
| Q3 25 | 3.7% | 35.7% | ||
| Q2 25 | -3.5% | 23.6% | ||
| Q1 25 | 5.9% | 20.7% | ||
| Q4 24 | 4.0% | 34.1% | ||
| Q3 24 | 9.2% | 26.0% | ||
| Q2 24 | 3.9% | 19.6% | ||
| Q1 24 | -11.1% | 28.8% |
| Q4 25 | 40.9% | 0.6% | ||
| Q3 25 | 28.4% | 1.6% | ||
| Q2 25 | 29.2% | 1.0% | ||
| Q1 25 | 20.2% | 1.8% | ||
| Q4 24 | 20.6% | 1.4% | ||
| Q3 24 | 12.6% | 2.0% | ||
| Q2 24 | 21.6% | 2.4% | ||
| Q1 24 | 26.3% | 1.1% |
| Q4 25 | 1.95× | 1.43× | ||
| Q3 25 | 2.45× | 2.22× | ||
| Q2 25 | 2.71× | 1.65× | ||
| Q1 25 | 2.41× | 1.10× | ||
| Q4 24 | 4.39× | 1.63× | ||
| Q3 24 | 3.65× | 1.55× | ||
| Q2 24 | 3.23× | 1.32× | ||
| Q1 24 | 3.63× | 1.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LTH
| Membership | $535.1M | 72% |
| In Center | $191.2M | 26% |
| Other | $18.8M | 3% |
MEDP
| Metabolic | $249.8M | 35% |
| Oncology | $195.9M | 28% |
| Other | $88.3M | 12% |
| Central Nervous System | $73.2M | 10% |
| Cardiology | $63.0M | 9% |
| Antiviral And Anti Infective | $38.3M | 5% |
| Related Party | $10.3M | 1% |
